PILA PHARMA presents at Aktiespararna
PILA PHARMA was listed on Nasdaq First North on July 15. After just over two months, it is time for CEO Dorte X. Gram to make a status update and present how the company is doing with the exciting development of a new drug for type 2 diabetes.
PILA PHARMA therefore participates in Aktiespararna's event Aktiedagen Lund, Tuesday, September 28, at 16.30.
We invite you as a shareholder, journalist, analyst, or just curious, to take part in the presentation live on the web, via www.aktiespararna.se/tv/live. The event is open to everyone and does not require membership in Aktiespararna. No pre-registration is required to follow the event digitally.
Please, take the opportunity to ask your questions to Dorte by sending an SMS to 079 - 347 98 45 or email [email protected]. Your questions will be conveyed by Aktiespararna's moderator in connection with the presentation. You can submit your questions now or in connection with the presentation.
Dorte X. Gram will hold the presentation in English.
When: Tuesday 28 September, 4.30 pm
Where: www.aktiespararna.se/tv/live
For more information:
Dorte X. Gram, CEO
M: +46 (0)73 903 6969
E: [email protected]
About PILA PHARMA
PILA PHARMA is a Swedish biotech company in the diabetes segment based in Malmö. The aim of the company is to develop a novel and superior tablet based treatment for type 2 diabetes. The company owns both use patents for treating diabetes and obesity with TRPV1 antagonists, and the intellectual property rights for the mid stage clinical development candidate XEN-D0501.
About XEN-D0501 and TRPV1 antagonists
XEN-D0501 is a highly selective and very potent small molecule TRPV1 antagonist, previously in development by Bayer Healthcare and Xention/Ario Pharma. The TRPV1 target (also called the "chili-receptor") has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes as well. XEN-D0501 was acquired by PILA PHARMA in March 2016, due to its very good safety and tolerability as compared to other clinical TRPV1-antagonist development candidates. TRPV1 antagonists as a drug-class has previously been associated with severe adverse events as fever (hyperthermia). The maximum tolerable dose in non-diabetic individuals has previously been determined to be 4 milligrams twice daily, a dose level with good safety but no effect in non-diabetic patients with either overactive bladder disease or chronic cough. In November 2018, PILA PHARMA reported the completion of its first clinical trial, PP-CT01, demonstrating good safety of XEN-D0501 at single doses up to 8 milligrams when administered to people with type 2 diabetes. The most recent study results were announced in September 2020. The study (PP-CT02) demonstrated that multiple doses of XEN-D0501 (4 mg twice daily for 28 days) were likewise safe and well-tolerated by people with type 2 diabetes and also - with statistical significance versus placebo - that XEN-D0501 enhances the endogenous insulin response to oral glucose, thus demonstrating proof of principle.
About diabetes
Diabetes is a world-wide pandemic with a staggering prevalence of 463 million diabetics corresponding to approximately 8-10% of the population. Approximately 90 % of all diabetics suffer from type 2 diabetes, whilst approximately 10% suffers from type 1 diabetes. The disease can lead to cardiovascular disease resulting in reduction of quality of life for the patient, increased risk of death and high health care expenses. Despite recent therapeutic advances, large and growing unmet needs exist both from an efficacy, safety, adherence, accessibility and affordability perspective.
Om PILA PHARMA
Prenumerera
Få löpande information från PILA PHARMA via e-post.